Page 44 - Summer2014

12. Kamboh, MI. Apolipoprotein E polymorphism and suscep- Neurobiol Aging 2001;22(3):397-402.
tibility to Alzheimer’s disease. Hum Bil 1995;67:195-215. 36. Cordain, L Eaton SB, Sebastian A, et al. Origins and evolution of the Western diet: health
13. Qiu W and Folstein M. Insulin, insulin-degrading enzyme implications for the 21st century. Am J Clin Nutr 2005;81:341-354.
and amyloid-β peptide in Alzheimer’s disease: review and 37. Cordain L Eaton SB. Evolutionary aspects of diet: old genes, new fuels. World Rev Nutr Diet
hypothesis, Neuro Biol Aging 2006;27:190-198 1997;81:26-37
14. Krikorian R, Shidler M, Dangelo K, et al. Dietary ketosis 38. Viola KL, Velasco PT, Klein WL. Why Alzheimer’s is a disease of memory: the attack on
enhances memory in mild cognitive impairment. Neurobiol- synapses by A beta oligomers (ADDLs). J Nutr Health Aging 2008;12(1):51S-7S.
ogy of Aging 2012;33:425e19-425e27. 39. Woods S, Seeley R, Baskin D, et al. Insulin and the blood-brain barrier. Curr Pharm Des
15. Kroner Z. The relationship between Alzheimer’s disease and 2003;9(10):795-800.
diabetes: Type 3 diabetes? Altern Med Rev. 2009;14(4):373-9. 40. Craft S, Peskind E, Schwartz M, et al. Cerebrospinal fluid and plasma insulin levels in
16. Irie F, Fitzpatrick A, Lopez O, et al. Enhanced risk for Al- Alzheimer’s disease – relationship to severity of dementia and apolipoprotein E genotype.
zheimer disease in persons with type 2 diabetes and APOE Neurology 1998;50:164-168.
ε4. Arch Neurol 2008;65(1):89-93. 41. Convit, A. Links between cognitive impairment in insulin resistance: an explanatory model.
17. Peila R, Rodriguez B, and Launer L. Type 2 diabetes, APOE Neurobiol Aging 2005;26 Suppl 1:31-5.
gene, and the risk for dementia and related pathologies – the 42. Watson G, Peskind E, Asthana S, et al. Insulin increases CSF Aβ42 levels in normal older adults.
Honolulu-Asia aging study. Diabetes 2002;51:1256-1262. Neurology 2003;60(12):1899-903.
18. Moreira P, Santos M, Sena C, et al. CoQ10 therapy attenuates 43. Luchsinger J, Tang M-X, Shea S, et al. Hyperinsulinemia and risk of Alzheimer's disease.
amyloid β-peptide toxicity in brain mitochondria isolated Neurology 2004;63:1187-1192.
from aged diabetic rats. Exp Neurol 2005;196(1):112-9. 44. Greenwood CE, Kaplan RJ, Hebblethwaite S, et al. Carbohydrate-induced memory impairment
19. Ott A, Stolk R, Van Harskamp F, et al. Diabetes mellitus in adults with type 2 diabetes. Diabetes Care 2003;26(7):1961-6.
and the risk of dementia: the Rotterdam study. Neurology 45. Schubert D. Glucose metabolism and Alzheimer’s disease. Ageing Res Rev 2005;4(2):240-57.
1999;53(9)1937-42. 46. VanItallie T and Nufert T. Ketones: metabolism’s ugly duckling. Nutr Rev 2003;61(10):327-41.
20. Reiman E, Caselli R, Yun L, et al. Preclinical evidence of 47. Veech R. The therapeutic implications of ketone bodies: the effects of ketone bodies in patho-
Alzheimer’s disease in persons homozygous for the e4 allele logical conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial
for apolipoprotein E. NEJM 1996; 334(12):752-758. metabolism. Prostaglandins Leukot Essent Fatty Acids 2003;70(3):309-19.
21. Fukuyama H, Ogawa M, Yamauchi H, et al. Altered cerebral 48. Martin B, Mattson MP, Maudsley S. Caloric restriction and intermittent fasting: two potential
energy metabolism in Alzheimer disease: a PET study. J Nucl diets for successful brain aging. Ageing Res Rev 2006;5(3):332-53.
Med 1994;35(1):1-6. 49. Prolla TA, Mattson MP. Molecular mechanisms of brain aging and neurodegenerative disorders:
22. Correia S, Santos E, Carvalho C, et al. Insulin signaling, Lessons from dietary restriction. Trends Neurosci 2001;24(11 Suppl):S21-31.
glucose metabolism and mitochondria: Major players in Al- 50. Devlin T, ed. Textbook of Biochemistry with Clinical Correlations. Hoboken, NJ:John Wiley
zheimer’s disease and diabetes interrelation. Brain Research & Sons, Inc., 2011;691-702.
2012;1441:64-78. 51. Gasior M, Rogawski M, and Hartman A. Neuroprotective and disease-modifying effects of the
23. Corbo RM and Scacchi R. Apolipoprotein E (APOE) allele ketogenic diet. Behav Pharmacol 2006;17(5-6):431-9.
distribution in the world. Is APOE*4 a 'thrifty' allele? Ann 52. Kashiwaya Y, Takeshima T, Mori N, et al. D-β-Hydroxybutyrate protects neurons in models of
Hum Genet 1999;63(4):301-10. Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA 2000;97(10):5440-4.
24. Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabo- 53. Henderson S. Ketone bodies as a therapeutic for Alzheimer’s disease. Neurotherapeutics
lism predicts cognitive decline from normal aging. Neurobiol 2008;5(3):470-80.
Aging 2008;29(5):676-692. 54. Cordain L. The nutritional characteristics of a contemporary diet based on Paleolithic food
25. Tortora G, Derrickson B, eds. Principles of Anatomy groups. J Am Nutraceut Assoc 2002;5:15-24.
and Physiology. Hoboken, NJ: John Wiley & Sonds, Inc., 55. Siri-Tarino P, Sun Q, Hu F, et al. Meta-analysis of prospective cohort studies evaluating the
2006;474. association of saturated fat with cardiovascular disease. Am J Clin Nutr 2010;91(3):535-46.
26. Strittmatter W and Roses Allen. Apolipoprotein E and Al- 56. Eli Lilly and Company. Lilly Halts Development of Semagacestat for Alzheimer's Disease
zheimer’s disease. Annu Rev Neurosci 1996;19:53-77. Based on Preliminary Results of Phase III Clinical Trials. Aug 17, 2010. http://newsroom.lilly.
27. Cook D, Leverenz J, McMillan P, et al. Reduced hippocampal com/releasedetail.cfm?releaseid=499794.
insulin-degrading enzyme in late-onset Alzheimer’s disease 57. Miller B, Eckman E, Sambamurti K, et al. Amyloid-β peptide levels in brain are inversely
is associated with the apolipoprotein E-ε4 allele. Am J Pathol correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003;100(10)6221-6.
2003;162(1):313-9. 58. Lamson DW, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev
28. Xie L, Helmerhorst E, Taddei K, et al. Alzheimer’s β-amyloid 2002;7(3):218-35.
peptides compete with insulin for binding to the insulin 59. Cefalu WT, Rood J, Pinsonat P, et al. Characterization of the metabolic and physiologic re-
receptor. J Neurosci. 2002;22(10):RC221. sponse to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism
29. Qiu W, Walsh D, Ye Z, et al. Insulin-degrading enzyme regu- 2010;59(5):755-62.
lates extracellular levels of amyloid β-protein by degradation. 60. Denniston K, Topping J, Caret R. General, Organic, and Biochemistry. New York, NY;McGraw-
J Biol Chem 1998;273(49):32730-8. Hill, 2011;574 and 772-773.
30. Gasparini L, Gouras GK, Wang R, et al. Stimulation of 61. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to mod-
beta-amyloid precursor protein trafficking by insulin reduces erate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.
intraneuronal beta-amyloid and requires mitogen-activated Nutr Metab (Lond) 2009;6:31.
protein kinase signaling. J Neurosci 2001;21(8):2561-70. 62. Mielke MM, Zandi PP, Sjögren M, et al. High total cholesterol levels in late life associated with
31. Hoshi M, Takashima A, Noguchi K, et al. Regulation of mi- a reduced risk of dementia. Neurology 2005;64(10):1689-95.
tochondrial pyruvate dehydrogenase activity by tau protein 63. Mulder M, Ravid R, Swaab DF, et al. Reduced levels of cholesterol, phospholipids, and fatty
kinase I/glycogen synthase kinase 3beta in brain. Proc Natl acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4.
Acad Sci USA 1996;93(7):2719-23. Alzheimer Dis Assoc Disord 1998;12(3):198-203.
32. Schmechel DE, Saunders AM, Strittmatter WJ, et al. In- 64. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently
creased amyloid β-peptide deposition in cerebral cortex as modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J Alzheimer’s
a consequence of apolipoprotein E genotype in late-onset Dis 2008;13(3):323-31.
Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-53.
33. Takeuchi M, Sato T, Takino J, et al. Diagnostic utility of
serum or cerebrospinal fluid levels of toxic advanced glyca- INVESTORS NEEDED
tion end-products (TAGE) in early detection of Alzheimer’s
disease. Med Hypotheses 2007;69(9)1358-66. Let’s expose the government’s campaign against against raw milk
34. Li Y and Dickson D. Enhanced binding of advanced glyca-
tion endproducts (AGE) by the ApoE4 isoform links the farmers! A group of supporters of Wisconsin farmer Vernon Hershberger
mechanism of plaque deposition in Alzheimer’s disease. is doing a documentary about his criminal trial last year, and we need
Neur Letters 1997;26:155-158. financial and technical support. We’ve completed a trailer, now on to a
35. Shuvaev VV, Laffont I, Serot JM, et al. Increased protein
glycation in cerebrospinal fluid of Alzheimer's disease. rough cut. Contact David Gumpert, david@davidgumpert.com.
44 Wise Traditions SUMMER 2014 Wise Traditions

137720_text.indd 44 7/1/14 11:41 AM